Market of Rett Syndrome Pipeline Reviewed of 14 Companies and 23 Drug Profiles

PUNE, India, June 10, 2016 /PRNewswire/ --

RnRMarketResearch.com adds "Rett Syndrome - Pipeline Review, H1 2016" market research report that provides an overview of the Rett Syndrome's therapeutic pipeline with comprehensive information, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Rett Syndrome and special features on late-stage and discontinued projects.

Complete report on H1 2016 pipeline review of Rett Syndrome with 30 market data tables and 14 figures, spread across 118 pages is available at http://www.rnrmarketresearch.com/rett-syndrome-pipeline-review-h1-2016-market-report.html .

The report also reviews key players involved in the therapeutic development for Rett Syndrome and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Companies discussed in this Rett Syndrome Pipeline Review, H1 2016 report include Anavex Life Sciences Corp., ArmaGen Inc., Edison Pharmaceuticals, Inc., GW Pharmaceuticals Plc, Mitsubishi Tanabe Pharma Corporation, Neuren Pharmaceuticals Limited, Neurolixis Inc., Newron Pharmaceuticals S.p.A., OPKO Health, Inc., Oryzon Genomics S.A., PharmatrophiX, Inc., Raptor Pharmaceutical Corp., Sage Therapeutics, Inc. and Ultragenyx Pharmaceutical Inc.

Drug profiles discussed in this research report includes amlexanox, ANAVEX-273, CPT-157633, cysteamine DR, desipramine hydrochloride, fingolimod hydrochloride, Gene therapy to Activate MECP2 for Rett Syndrome, LM-22A4, NLX-101, Oligonucleotide For Rett Syndrome, ORY-2001, Recombinant Protein for Rett Syndrome, Recombinant Protein to Agonize BDNF for Rett Syndrome, REV-003, SAGE-217, sarizotan hydrochloride, Small Molecule to Activate TrkB Receptor for Central Nervous System, Metabolic Disorders and ENT Disorders, Small Molecules for Rett Syndrome, Small Molecules to Agonize Cannabinoid Receptor 2 for Fragile X Syndrome and Pervasive Developmental Disorder, trofinetide, UX-007 and vatiquinone.

Order a copy of Rett Syndrome - Pipeline Review, H1 2016 market research report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=608204 .

Scope of this report: The report provides a snapshot of the global therapeutic landscape of Rett Syndrome and reviews pipeline therapeutics for Rett Syndrome by companies and universities/research institutes based on information derived from company and industry-specific sources and key players involved Rett Syndrome therapeutics and enlists all their major and minor projects. The research covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages. The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities and assesses Rett Syndrome therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report summarizes all the dormant and discontinued pipeline projects with latest news related to pipeline therapeutics for Rett Syndrome.

Another newly published market research report titled on Peripheral Neuropathic Pain - Pipeline Review, H1 2016 also reviews key players involved in the therapeutic development for Peripheral Neuropathic Pain and special features on late-stage and discontinued projects. Companies Involved in Therapeutics Development are Achelios Therapeutics, Inc., AnaBios Corporation, Chromocell Corporation, Eli Lilly and Company, GW Pharmaceuticals Plc, Nektar Therapeutics, Phosphagenics Limited, Spherium Biomed S.L., Sunovion Pharmaceuticals Inc. and Zynerba Pharmaceuticals, Inc. Peripheral Neuropathic Pain Pipeline market research report of 70 pages is available at http://www.rnrmarketresearch.com/peripheral-neuropathic-pain-pipeline-review-h1-2016-market-report.html .

Explore more reports on Neurology therapeutics.

About Us:   

RnRMarketResearch.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.

Connect with Us:  

G+ / Google Plus: https://plus.google.com/104156468549256253075/posts

Twitter: https://twitter.com/RnRMR

Facebook: https://www.facebook.com/pages/RnR-Market-Research/413488545356345

RSS / Feeds: http://www.rnrmarketresearch.com/feed

Contact:
Ritesh Tiwari
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune - 411013
Maharashtra, India.
Tel:  +1-888-391-5441
sales@rnrmarketresearch.com

SOURCE RnR Market Research